Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Introduction: Major pathologic response after neoadjuvant chemotherapy (NAC) for NSCLC has been defined as 10% or less residual viable tumor without distinguishing between histologic types. We sought to investigate whether the optimal cutoff percentage of residual viable tumor for predicting survival differs between lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Methods: Tumor slides from 272 patients treated with NAC and surgery for clinical stage II‐III NSCLC (ADC, n = 192; SCC, n = 80) were reviewed. The optimal cutoff percentage of viable tumor for predicting lung cancer–specific cumulative incidence of death (LC‐CID) was determined using maximally selected rank statistics. LC‐CID was analyzed using a competing‐risks approach. Overall survival was evaluated using Kaplan‐Meier methods and Cox proportional hazard analysis. Results: Patients with SCC had a better response to NAC (median percentage of viable tumor: SCC versus ADC, 40% versus 60%; p = 0.027). Major pathologic response (≤10% viable tumor) was observed in 26% of SCC cases versus 12% of ADC cases (p = 0.004). The optimal cutoff percentage of viable tumor for LC‐CID was 10% for SCC and 65% for ADC. On multivariable analysis, viable tumor 10% or less was an independent factor for better LC‐CID (p = 0.035) in patients with SCC; in patients with ADC, viable tumor 65% or less was a factor for better LC‐CID (p = 0.033) and overall survival (p = 0.050). Conclusions: In response to NAC, the optimal cutoff percentage of viable tumor for predicting survival differs between ADC and SCC. Our findings have implications for the pathologic assessment of resected specimens, especially in upcoming clinical trials design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring agreement in method comparison studies
Bland, J. M., & Altman, D. G. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800204 · Cited by 9,619
Measuring agreement in method comparison studies
Bland, J. M., & Altman, D. G. (1999) · Statistical Methods in Medical Research · doi:10.1191/096228099673819272 · Cited by 9,619
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“Pack-years 32 (17, 50) 27 (12, 45) 42 (30, 60) <0.”
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0232 · Cited by 690
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Self-citationPataer, A., Kalhor, N., Correa, A. M., Raso, M. G., Erasmus, J. J., Kim, E. S., Behrens, C., Lee, J. J., Roth, J. A., Stewart, D. J., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318247504a · Cited by 374 · cited 1×
“N2b 36 (13) 32 (17) 4 (5) ypStage based on tumor bed size”
William, W. N., Pataer, A., Kalhor, N., Correa, A. M., Rice, D. C., Wistuba, I. I., Heymach, J., Lee, J. J., Kim, E. S., Munden, R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182774108 · Cited by 138
Chaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., Price, K. A. R., Azzoli, C. G., Fury, M. G., Riely, G. J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829923ec · Cited by 122 · cited 1×
“(ADC þ SCC) and SCC cohorts, thus validating its use for these patients; (2) however, MPR ( 10% viable tumor) was not significantly associated with survival in the ADC cohort; and (3) the optimal cutoff for predicting lung cancer–specific death differed between histologic types—10% in SCC and 65% in ADC—and these cuto…”
Self-citation
Cited by
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Shu, C. A., Gainor, J. F., Awad, M. M., Chiuzan, C., Grigg, C. M., Pabani, A., Garofano, R. F., Stoopler, M. B., Cheng, S. K., White, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30140-6 · Cited by 623
Travis, W. D., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.005 · Cited by 465
Self-citationProvencio, M., Serna-Blasco, R., Nadal, E., Insa, A., García-Campelo, M. R., Casal Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02660 · Cited by 349
Zhong, W.-Z., Chen, K.-N., Chen, C., Gu, C.-D., Wang, J., Yang, X.-N., Mao, W.-M., Wang, Q., Qiao, G.-B., Cheng, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00075 · Cited by 268
Metadata
- Authors
- Qu, Y., Emoto, K., Eguchi, T., Aly, R. G., Zheng, H., Chaft, J. E., Tan, K. S., Jones, D. R., Kris, M. G., Adusumilli, P. S., & Travis, W. D.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 14
- Issue
- 3
- Pages
- 482-493
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2902193335
- Cited by
- 118
- References
- 9
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. https://app.cochat.ai/papers/10.1016/j.jtho.2018.11.017
- The paper
- Qu, Y., Emoto, K., Eguchi, T., Aly, R. G., Zheng, H., Chaft, J. E., Tan, K. S., Jones, D. R., Kris, M. G., Adusumilli, P. S., & Travis, W. D. (2019). Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.11.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.